Zoster Meningitis in an Immunocompetent Child after COVID-19 Vaccination, California, USA
Sarah K. Daouk, Edwin Kamau, Kristina Adachi, Grace M. Aldrovandi
Abstract
T he COVID-19 mRNA vaccines authorized in the United States are highly effective and safe, causing few adverse events (1). Cases of varicella zoster virus (VZV) reactivation after COVID-19 vaccination have been reported, but most occurred in older adults with comorbid conditions and known risk factors for VZV reactivation (2,3). We report a case of zoster meningitis reactivation from live-attenuated varicella vaccine (vOka) in a healthy child, occurring in close temporal relation with Pfizer-BioNTech (https:// www.pfizer.com) BNT162b2 vaccination.
Topics & Concepts
VaccinationMedicineMeningitisCoronavirus disease 2019 (COVID-19)Chickenpox VaccineVirologyPediatricsVaricella zoster virusImmunologyPopulationVaricella vaccineVirusImmunizationImmune systemEnvironmental healthDiseaseInternal medicineInfectious disease (medical specialty)Herpesvirus Infections and TreatmentsBartonella species infections researchFood Allergy and Anaphylaxis Research